AAV9基因治疗II型GM1神经节苷脂沉积症的1-2期试验
本研究为1-2期开放标签剂量递增试验,评估免疫抑制联合单次静脉输注AAV9载体(编码β-半乳糖苷酶)治疗9例晚发婴儿型或青少年型II型GM1神经节苷脂沉积症患儿的安全性和疗效。主要终点为安全性,结果显示所有患儿出现肝酶升高,1例因严重呕吐住院,但脑脊液β-半乳糖苷酶升高、GM1神经节苷脂下降,神经影像提示脑萎缩减缓及髓鞘化改善,部分发育指标稳定。
要点
- AAV9基因治疗在II型GM1神经节苷脂沉积症患儿中可升高脑脊液酶活性并降低底物水平。
- 所有患儿出现肝酶升高,多数在18个月内恢复,1例发生治疗相关严重呕吐。
- 部分发育指标稳定或下降减缓,神经影像提示脑萎缩减缓及髓鞘化改善。
核心结论
- 单次静脉输注AAV9编码β-半乳糖苷酶与不良事件相关,包括1例严重呕吐和所有患儿肝酶升高。
- 次要终点结果提示生化标志物和神经影像改善,部分发育指标稳定或恶化减缓。
研究设计与样本
- 1-2期、开放标签、剂量递增研究,纳入9例晚发婴儿型或青少年型II型GM1神经节苷脂沉积症患儿。
- 干预为免疫抑制联合单次静脉输注AAV9载体(编码β-半乳糖苷酶),主要终点为安全性。
主要发现
- 3年期间共发生124例不良事件,其中30例(8例胃肠道事件、21例炎症相关实验室异常、1例心动过速)被研究者判定可能与基因治疗相关。
- 发生5例严重不良事件,包括1例因呕吐住院并归因于基因治疗。
- 所有患儿血清天冬氨酸和丙氨酸氨基转移酶升高,18个月时恢复至基线水平。
- 所有患儿脑脊液β-半乳糖苷酶水平升高、GM1神经节苷脂水平下降。
- 表达性沟通和粗大运动评分似乎稳定,但精细运动及接受性沟通评分下降;2年时CGI-I中位评分为3(轻微改善),3年时为4(无变化)。
临床怎么用
- 该治疗仍处于早期试验阶段,需进一步验证安全性和疗效后方可临床推广。
- 治疗相关肝酶升高和严重呕吐需密切监测。
局限性
- 样本量小(9例),为开放标签、剂量递增设计,无同期对照组。
- 使用历史对照比较CGI-I评分,可能存在偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: GM1 gangliosidosis, caused by biallelic variants in GLB1, results from deficiency of lysosomal β-galactosidase, which degrades GM1 ganglioside. This fatal neurodegenerative disease currently has no effective therapy. METHODS: In a phase 1-2, open-label, dose-escalation study, we assessed immunosuppression and a single intravenous infusion of adeno-associated virus serotype 9 (AAV9) encoding β-galactosidase in children with type II GM1 gangliosidosis with late-infantile or juvenile onset. The primary end point was safety. Secondary end points included changes from baseline in the cerebrospinal fluid (CSF) GM1 ganglioside concentration and β-galactosidase activity, clinical assessments (including the Clinical Global Impression-Improvement [CGI-I] score, assessed on a scale from 1 [very much improved] to 7 [very much worse]), and neuroimaging patterns. RESULTS: Nine participants were enrolled. Over a 3-year period, 124 adverse events occurred, 30 of which (8 gastrointestinal events, 21 laboratory abnormalities associated with inflammation, and 1 tachycardia event) were deemed by the investigator as being possibly, probably, or definitely related to the gene therapy. Five serious adverse events occurred, including vomiting that led to hospitalization in one participant, which was attributed to the gene therapy. Serum aspartate and alanine aminotransferase levels increased in all participants and returned to baseline levels by 18 months. In all participants, the CSF β-galactosidase level increased and CSF GM1 ganglioside level decreased. Expressive communication and gross motor scores appeared stable, but fine motor and receptive communication scores decreased. The median CGI-I score was 3 (indicating minimal improvement) at 2 years and 4 (indicating no change) at 3 years; in historical controls, scores have been shown to increase (indicating worsening) over time. Neuroimaging showed patterns consistent with reduced rates of cerebral atrophy and favorable changes in myelination as compared with baseline. CONCLUSIONS: In this study involving nine participants with type II GM1 gangliosidosis, a single infusion of AAV9 encoding β-galactosidase was associated with adverse events, including severe vomiting in one participant and elevated liver-enzyme levels in all participants. Secondary end-point results suggested improvements in biochemical markers and neuroimaging patterns and stable or reduced rates of developmental deterioration in some measures. (Funded by the National Human Genome Research Institute and others; ClinicalTrials.gov number, NCT03952637.).
引用
- Lewis CJ, D'Souza P, Johnston JM, et al. AAV9 Gene Therapy in Type II GM1 Gangliosidosis - A Phase 1-2 Trial. N Engl J Med. 2026. PMID: 41665410. doi:10.1056/NEJMoa2510935
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。